Alban, JP, Hopson, MM, Ly, V et al (2004) Effect of methylphenidate on vital signs and adverse effects in adults with traumatic brain injury. American Journal of Physical Medicine and Rehabilitation; 83: 131–7.
Berigan, T (2004) Modafinil treatment of excessive sedation associated with divalproex sodium. Canadian Journal of Psychiatry; 49: 72–3.
Block, SD (2000) Assessing and managing depression in the terminally ill patient. Annals of Internal Medicine; 132: 209–18.
Blockmans, D, Persoons, P, van Houdenhove, B et al (2006) Does methylphenidate reduce the symptoms of chronic fatigue syndrome?
American Journal of Medicine; 119: 167.e23–30.
Breitbart, W, Rosenfeld, B, Kaim, M et al (2001) A randomized, double-blind, placebo-controlled trial of psychostimulants for the treatment of fatigue in ambulatory patients with human immunodeficiency virus disease. Archives of Internal Medicine; 161: 411–20.
Bruera, E, Valero, V, Driver, L et al (2006) Patient-controlled methylphenidate for cancer fatigue. A double-blind, randomized, placebo-controlled trial. Journal of Clinical Oncology; 24: 2073–8.
Carlson, PJ, Merlock, MC, Suppes, T (2004) Adjunctive stimulant use in patients with bipolar disorder. Treatment of residual depression and sedation. Bipolar Disorders; 6: 416–20.
Challman, TD, Lipsky, JJ (2000) Methylphenidate. Its pharmacology and uses. Mayo Clinic Proceedings; 75: 711–21.
Chiarello, RJ, Cole, JO (1987) The use of psychostimulants in general psychiatry. A reconsideration. Archives of General Psychiatry; 44: 286–95.
Dackis, CA, Kampman, KM, Lynch, KG et al (2005) A double-blind, placebo-controlled trial of modafinil for cocaine dependence. Neuropsychopharmacology; 30: 205–11.
DeBattista, C, Doghramji, K, Menza, MA et al (2003) Adjunct modafinil for the short-term treatment of fatigue and sleepiness in patients with major depressive disorder. A preliminary double-blind, placebo-controlled study. Journal of Clinical Psychiatry; 64: 1057–64.
Fava, M, Thase, ME, DeBattista, C (2005) A multicenter, placebo-controlled study of modafinil augmentation in partial responders to selective serotonin reuptake inhibitors with persistent fatigue and sleepiness. Journal of Clinical Psychiatry; 66: 85–93.
Feinberg, SS (2004) Combining stimulants with monoamine oxidase inhibitors. A review of uses and one possible additional indication. Journal of Clinical Psychiatry; 65: 1520–4.
Fernandez, F, Levy, JK, Samley, HR et al (1995) Effects of methylphenidate in HIV-related depression. A comparative trial with desipramine. International Journal of Psychiatry in Medicine; 25: 53–67.
Frierson, RL, Wey, JJ, Tabler, JB (1991) Psychostimulants for depression in the medically ill. American Family Physician; 43: 163–70.
Frye, MA, Grunze, H, Suppes, T et al (2007) A placebo-controlled evaluation of adjunctive modafinil in the treatment of bipolar depression. American Journal of Psychiatry; 164: 1242–9.
Galynker, I, Ieronimo, C, Miner, C et al (1997) Methylphenidate treatment of negative symptoms in patients with dementia. Journal of Neuropsychiatry and Clinical Neurosciences; 9: 231–9.
Grabowski, J, Roache, JD, Schmitz, JM et al (1997) Replacement medication for cocaine dependence. Methylphenidate. Journal of Clinical Psychopharmacology; 17: 485–8.
Grade, C, Redford, B, Chrostowski, J et al (1998) Methylphenidate in early post-stroke recovery. A double-blind, placebo-controlled study. Archives of Physical Medicine and Rehabilitation; 79: 1047–50.
Gualtieri, CT, Evans, RW (1988) Stimulant treatment for the neurobehavioral sequelae of traumatic brain injury. Brain Injury; 2: 273–90.
Gwirtsman, HE, Szuba, MP, Toren, L et al (1994) The antidepressant response to tricyclics in major depressives is accelerated with adjunctive use of methylphenidate. Psychopharmacology Bulletin; 30: 157–64.
Hinkin, CH, Castellon, SA, Hardy, DJ et al (2001) Methylphenidate improves HIV-1-associated cognitive slowing. Journal of Neuropsychiatry and Clinical Neurosciences; 13: 248–54.
Homsi, J, Walsh, D, Nelson, KA (2000) Psychostimulants in supportive care. Support Care in Cancer; 8: 385–97.
Jacobson, A (1958) The use of Ritalin in psychotherapy of depressions of the aged. Psychiatric Quarterly; 32: 474–83.
Jasinski, DR (2000) An evaluation of the abuse potential of modafinil using methylphenidate as a reference. Journal of Psychopharmacology; 14: 53–60.
Kaelin, DL, Cifu, DX, Matthies, B (1996) Methylphenidate effect on attention deficit in the acutely brain-injured adult. Archives of Physical Medicine and Rehabilitation; 77: 6–9.
Kaplitz, SE (1975) Withdrawn, apathetic geriatric patients responsive to methylphenidate. Journal of the American Geriatrics Society; 23: 271–6.
Keating, GM, Raffin, MJ (2005) Modafinil. A review of its use in excessive sleepiness associated with obstructive sleep apnoea/hypopnoea syndrome and shift work sleep disorder. CNS Drugs; 19: 785–803.
Keen, JC, Brown, D (2004) Psychostimulants and delirium in patients receiving palliative care. Palliative & Supportive Care; 2: 199–202.
Kraus, MF (1995) Neuropsychiatric sequelae of stroke and traumatic brain injury. The role of psychostimulants. International Journal of Psychiatry in Medicine; 25: 39–51.
Lam, JY, Freeman, MK, Cates, ME (2007) Modafinil augmentation for residual symptoms of fatigue in patients with a partial response to antidepressants. Annals of Pharmacotherapy; 41: 1005–12.
Landman, ME, Peisig, R, Perlman, M (1958) A practical mood stimulant. Journal of the Medical Society of New Jersey; 55: 55–8.
Lavretsky, H, Park, S, Siddarth, P et al (2006) Methylphenidate-enhanced antidepressant response to citalopram in the elderly. A double-blind, placebo-controlled pilot trial. American Journal of Geriatric Psychiatry; 14: 181–5.
Lazarus, LW, Moberg, PJ, Langsley, PR et al (1994) Methylphenidate and nortriptyline in the treatment of poststroke depression. A retrospective comparison. Archives of Physical Medicine and Rehabilitation; 75: 403–6.
Lee, H, Kim, S-W, Kim, J-M et al (2005) Comparing effects of methylphenidate, sertraline and placebo on neuropsychiatric sequelae in patients with traumatic brain injury. Human Psychopharmacology; 20: 97–104.
Martin, RT, Whyte, J (2007) The effects of methylphenidate on command following and yes/no communication in persons with severe disorders of consciousness. A meta-analysis of n-of-1 studies. American Journal of Physical Medicine and Rehabilitation; 86: 613–20.
Martinsson, L, Hårdemark, H-G, Eksborg, S (2007) Amphetamines for improving recovery after stroke. Cochrane Database of Systematic Reviews; issue 1: CD002090.
Masand, PS, Pickett, P, Murray, GB (1995) Hypomania precipitated by psychostimulant use in depressed medically ill patients. Psychosomatics; 36: 145–7.
Masand, PS, Tesar, GE (1996) Use of stimulants in the medically ill. Psychiatric Clinics of North America; 19: 516–47.
Masand, PS, Anand, VS, Tanquary, JF (1998) Psychostimulant augmentation of second generation antidepressants. A case series. Depression and Anxiety; 7: 89–91.
Medicines and Healthcare products Regulatory Agency (2008) Modafinil: serious skin reactions, hypersensitivity, and psychiatric symptoms. Drug Safety Update; 1(8): 5.
Medicines and Healthcare products Regulatory Agency (2009) Methylphenidate: update guidance on safe and effective use in ADHD. Drug Safety Update; 2(8): 2.
Miller, SC (1996) Methylphenidate for clozapine sedation. American Journal of Psychiatry; 153: 1231–2.
Mooney, GF, Haas, LJ (1993) Effect of methylphenidate on brain injury-related anger. Archives of Physical Medicine and Rehabilitation; 74: 153–60.
Moore, DP (1981) Methylphenidate in depression and states of apathy. Southern Medical Journal; 74: 347–8.
Narendran, R, Young, CM, Valenti, AM et al (2002) Is psychosis exacerbated by modafinil?
Archives of General Psychiatry; 59: 292–3.
Ninan, PT, Hassman, HA, Glass, SJ et al (2004) Adjunctive modafinil at initiation of treatment with a selective serotonin reuptake inhibitor enhances the degree and onset of therapeutic effects in patients with major depressive disorder and fatigue. Journal of Clinical Psychiatry; 65: 414–20.
Nissen, SE (2006) ADHD drugs and cardiovascular risk. New England Journal of Medicine; 354: 1445–8.
Olson, LG, Ambrogetti, A, Sutherland, DC (2003) A pilot randomized controlled trial of dexamphetamine in patients with chronic fatigue syndrome. Psychosomatics; 44: 38–43.
Orr, K, Taylor, D (2007) Psychostimulants in the treatment of depression. A review of the evidence. CNS Drugs; 21: 239–57.
Padala, PR, Burke, WJ, Bhatia, SC (2007) Modafinil therapy for apathy in an elderly patient. Annals of Pharmacotherapy; 41: 346–9.
Patkar, AA, Masand, PS, Pae, C–U et al (2006) A randomized, double-blind, placebo-controlled trial of augmentation with an extended release formulation of methylphenidate in outpatients with treatment-resistant depression. Journal of Clinical Psychopharmacology; 26: 653–6.
Plenger, PM, Dixon, CE, Castillo, RM et al (1996) Subacute methylphenidate treatment for moderate to moderately severe traumatic brain injury. A preliminary double-blind placebo-controlled study. Archives of Physical Medicine and Rehabilitation; 77: 536–40.
Postolache, TT, Rosenthal, RN, Hellerstein, DJ et al (1999) Early augmentation of sertraline with methylphenidate. Journal of Clinical Psychiatry; 60: 123–4.
Rabkin, JG, McElhiney, MC, Rabkin, R et al (2004) Modafinil treatment for fatigue in HIV+ patients. A pilot study. Journal of Clinical Psychiatry; 65: 1688–95.
Randall, DC, Cafferty, FH, Shneerson, JM et al (2005) Chronic treatment with modafinil may not be beneficial in patients with chronic fatigue syndrome. Journal of Psychopharmacology; 19: 647–60.
Rosenthal, MH, Bryant, SL (2004) Benefits of adjunct modafinil in an open-label, pilot study in patients with schizophrenia. Clinical Neuropharmacology; 27: 38–43.
Rozans, M, Dreisbach, A, Lertora, JJL et al (2002) Palliative uses of methylphenidate in patients with cancer. A review. Journal of Clinical Oncology; 20: 335–9.
Satel, SL, Nelson, JC (1989) Stimulants in the treatment of depression. A critical overview. Journal of Clinical Psychiatry; 50: 241–9.
Schillerstrom, JE, Seaman, JS (2002) Modafinil augmentation of mirtazapine in a failure-to-thrive geriatric inpatient. International Journal of Psychiatry in Medicine; 32: 405–10.
Schwartz, TL, Leso, L, Beale, M et al (2002) Modafinil in the treatment of depression with severe comorbid medical illness. Psychosomatics; 43: 336–7.
Schwartz, TL, Azhar, N, Cole, K et al (2004) An open-label study of adjunctive modafinil in patients with sedation related to serotonergic antidepressant therapy. Journal of Clinical Psychiatry; 65: 1223–7.
Sevy, S, Rosenthal, MH, Alvir, J et al (2005) Double-blind, placebo-controlled study of modafinil for fatigue and cognition in schizophrenia patients treated with psychotropic medications. Journal of Clinical Psychiatry; 66: 839–43.
Sonde, L, Lökk, J (2007) Effects of amphetamine and/or L-dopa and physiotherapy after stroke. A blinded randomized study. Acta Neurologica Scandinavica; 115: 55–9.
Speech, TJ, Rao, SM, Osmon, DC et al (1993) A double-blind controlled study of methylphenidate treatment in closed head injury. Brain Injury; 7: 333–8.
Wagner, GJ, Rabkin, R (2000) Effects of dextroamphetamine on depression and fatigue in men with HIV. A double-blind, placebo-controlled trial. Journal of Clinical Psychiatry; 61: 436–40.
Wallace, AE, Kofoed, LL, West, AN (1995) Double-blind, placebo-controlled trial of methylphenidate in older, depressed, medically ill patients. American Journal of Psychiatry; 152: 929–31.
Whyte, J, Hart, T, Schuster, K et al (1997) Effects of methylphenidate on attentional function after traumatic brain injury. A randomized, placebo-controlled trial. American Journal of Physical Medicine and Rehabilitation; 76: 440–450.
Whyte, J, Vaccaro, M, Grieb-Neff, P et al (2002) Psychostimulant use in the rehabilitation of individuals with traumatic brain injury. Journal of Head Trauma Rehabilitation; 17: 284–99.
Whyte, J, Hart, T, Vaccaro, M et al (2004) Effects of methylphenidate on attention deficits after traumatic brain injury. A multidimensional, randomized, controlled trial. American Journal of Physical Medicine and Rehabilitation; 83: 401–19.